Agile Therapeutics (AGRX)
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Forecast & Price Target

1,454 Followers
See the Price Targets and Ratings of:

AGRX Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Agile
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGRX Stock 12 Months Forecast

Average Price Target

$1.00
▲(431.35% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Agile Therapeutics in the last 3 months. The average price target is $1.00 with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 431.35% change from the last price of $0.19.
Highest Price Target$1.00Average Price Target$1.00Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
H.C. Wainwright
$5.00
Buy
2556.75%
Upside
Reiterated
We see no reason Twirla should slow down at just ~3% Rx share in June of transdermal hormonal contraceptive patches despite being clearly differentiated from the alternative high-dose, less-safe Xulane and generic patch, which do near 2M annual prescriptions. Twirla should get tailwinds from Washington finally looking ready to start enforcing compliance with Affordable Care Act (ACA) provisions assuring women straightforward, no-cost access to contraceptives of their choice, especially in the wake of Roe being overturned.
Oppenheimer
$60.00
Buy
31780.98%
Upside
Reiterated
Agile Therapeutics (AGRX) PT Lowered to $1.50 at OppenheimerOppenheimer analyst Leland Gershell lowered the price target on Agile Therapeutics (NASDAQ: AGRX) to $1.50 (from $4.00) while maintaining a Outperform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AGRX Financial Forecast

AGRX Earnings Forecast
Next quarter’s earnings estimate for AGRX is -$0.23 with a range of -$0.23 to -$0.23. The previous quarter’s EPS was -$0.53. AGRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.43% of the time in the same period. In the last calendar year AGRX has Underperformed its overall industry.
Next quarter’s earnings estimate for AGRX is -$0.23 with a range of -$0.23 to -$0.23. The previous quarter’s EPS was -$0.53. AGRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.43% of the time in the same period. In the last calendar year AGRX has Underperformed its overall industry.
AGRX Sales Forecast
Next quarter’s sales forecast for AGRX is $3.08M with a range of $3.08M to $3.08M. The previous quarter’s sales results were $3.00M. AGRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year AGRX has Outperformed its overall industry.
Next quarter’s sales forecast for AGRX is $3.08M with a range of $3.08M to $3.08M. The previous quarter’s sales results were $3.00M. AGRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year AGRX has Outperformed its overall industry.
AGRX Analyst Recommendation Trends
In the current month, AGRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AGRX average analyst price target in the past 3 months is $1.00
In the current month, AGRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AGRX average analyst price target in the past 3 months is $1.00

AGRX Stock Forecast FAQ

What is AGRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Agile Therapeutics’s 12-month average price target is $1.00.
    What is AGRX’s upside potential, based on the analysts’ average price target?
    Agile Therapeutics has 431.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGRX a Buy, Sell or Hold?
          Agile Therapeutics has a conensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Agile Therapeutics’s price target?
            The average price target for Agile Therapeutics is $1.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1.00 ,the lowest forecast is $1.00. The average price target represents 431.35% Increase from the current price of $0.188.
              What do analysts say about Agile Therapeutics?
              Agile Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis